H.C. Wainwright Maintains Zymeworks(ZYME.US) With Hold Rating, Maintains Target Price $10
H.C. Wainwright analyst Robert Burns maintains $Zymeworks(ZYME.US)$ with a hold rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 0.0% and a t
Zymeworks Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 17.1% HC Wainwright & Co. $10 → $10 Reiterates Buy → Buy 06/06/2024 17.1% HC Wainwright & Co. $
Zymeworks ZW171 IND for Mesothelin-expressing Cancers Cleared by FDA
Market-Moving News for June 17th
BBY: 4% | UBS Upgrades Best Buy Co to Buy, Raises Price Target to $106ZYME: 13% | Zymeworks shares are trading higher after the FDA cleared the company's Investigational New Drug application for Zw171
Express News | Zymeworks Shares up 4.1% Premarket After FDA Clears Co's Application to Start Trials in Humans for Cancer Drug
Zymeworks Gets FDA OK to Study ZW171 for Mesothelin-Expressing Cancers
By Colin Kellaher Zymeworks has won Food and Drug Administration approval to begin studies of ZW171, a bispecific antibody targeting mesothelin-expressing cancers. The Middletown, Del., clinical-sta
Express News | Zymeworks: To File Applications Seeking Regulatory Permission to Commence Clinical Studies for ZW171 in Other Non-US Jurisdictions in H2 2024
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a Novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
The Company expects to file applications seeking regulatory permission to commence clinical studies for ZW171 in other non-US jurisdictions in the second half of 2024.
Express News | Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a Novel 2+1 T-Cell Targeting Bispecific Antibody for Mesothelin-Expressing Cancers
Zymeworks (NASDAQ:ZYME) Investors Are Sitting on a Loss of 75% If They Invested Three Years Ago
Subdued Growth No Barrier To Zymeworks Inc.'s (NASDAQ:ZYME) Price
It's not a stretch to say that Zymeworks Inc.'s (NASDAQ:ZYME) price-to-sales (or "P/S") ratio of 13.6x right now seems quite "middle-of-the-road" for companies in the Biotechs industry in the United
Form 144 | Zymeworks(ZYME.US) Insider Proposes to Sell 774.06K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 11, $Zymeworks(ZYME.US)$ Insider Christopher Astle intends to sell 86,294 shares of its common stock on Jun 11, with a total market value of approximately $774.06K. Sour
Sector Update: Health Care Stocks Decline Premarket Monday
Health care stocks were declining premarket Monday as the iShares Biotechnology ETF (IBB) was 0.5% lower and the Health Care Select Sector SPDR Fund (XLV) was down 0.3% recently. Skye Bioscience (SKYE
Zymeworks Says China's Health Regulator Accepts Biologics License Application for Cancer Therapy
Zymeworks (ZYME) said Monday that China's health regulator has accepted the Biologics License Application for its second-line experimental treatment of HER2-positive biliary tract cancer, zanidatamab.
Zymeworks' BLA For Zanidatamab For HER2-positive BTC Accepted By CDE In China
Zymeworks Achieves Key Milestone With BLA Acceptance for Zanidatamab in China, Zymeworks to Receive Up to $164M in Milestone Payments
Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat dise
Express News | Zymeworks Inc: Priority Review by FDA With Target Action Date of November 29, 2024
Express News | Zymeworks Inc: Zymeworks Remains Eligible to Receive up to $164 Mln Based on Additional Milestones Plus Royalties on Product Sales
Express News | Zymeworks Inc: Zymeworks Is Entitled to Receive an $8 Mln Milestone Payment From Beigene
Express News | Zymeworks Announces China Nmpa Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer